Department of Anesthesiology, The First Central Hospital of Baoding, Northern Greatwall Street 320#, Baoding, 071000, Hebei, China.
Department of Orthopedics, The First Center Hospital of Baoding, Baoding, 071000, Hebei, China.
BMC Anesthesiol. 2022 Jun 6;22(1):175. doi: 10.1186/s12871-022-01712-7.
The optimal analgesia for total knee arthroplasty (TKA) requires excellent analgesia while preserving muscle strength. This study aimed to determine the hypothesis that continuous adductor canal block (CACB) combined with the distal interspace between the popliteal artery and the posterior capsule of the knee (IPACK) block could effectively alleviate the pain of the posterior knee, decrease opioids consumption, and promote early recovery and discharge.
Patients undergoing unilateral, primary TKA were allocated into group CACB+SHAM (receiving CACB plus sham block) or group CACB+IPACK (receiving CACB plus IPACK block). The primary outcome was cumulative opioid consumption. Secondary outcomes included the incidence of postoperative pain originated from the posterior knee, visual analogue scale (VAS) score, range of motion, ambulation distance, and satisfaction for pain management.
The incidence of moderate-severe pain of the posterior knee was lower in group CACB+IPACK than that of the group CACB+SHAM at 4 hours (17.1% vs. 42.8%; p = 0.019), 8 hours (11.4% vs. 45.7%; p = 0.001), and 24 hours (11.4% vs. 34.3%; p = 0.046) after TKA. The VAS scores of the posterior knee were lower in group CACB+IPACK than that of the group CACB+SHAM at 4 hours [2 (2) vs. 3 (2-4); p = 0.000], 8 hours [1 (1, 2) vs. 3 (2-4); p = 0.001], and 24 hours [1(0-2) vs. 2 (1-4); p = 0.002] after TKA. The overall VAS scores were lower in group CACB+IPACK than that of the group CACB+SHAM at 4 hours [3 (2, 3) vs. 3 (3, 4); p = 0.013] and 8 hours [2 (2, 3) vs. 3 (2-4); p = 0.032] at rest and 4 hours [3 (3, 4) vs. 4 (4, 5); p = 0.001], 8 hours [3 (2-4) vs. 4 (3-5); p = 0.000], 24 hours [2 (2, 3) vs. 3 (2-4); p = 0.001] during active flexion after TKA. The range of motion (59.11 ± 3.90 vs. 53.83 ± 5.86; p = 0.000) and ambulation distance (44.60 ± 4.87 vs. 40.83 ± 6.65; p = 0.009) were superior in group CACB+IPACK than that of the group CACB+SHAM in postoperative day 1. The satisfaction for pain management was higher in group CACB+IPACK than that of the group CACB+SHAM [9 (8, 9) vs. 8 (7-9); p = 0.024]. There was no difference in term of cumulative opioids consumption between group CACB+IPACK and group CACB+SHAM [120(84-135) vs. 120(75-135); p = 0.835].
The combination of CACB and distal IPACK block could decrease the incidences of moderate-severe posterior knee pain, improve the postoperative pain over the first 24 hours after TKA, as well as promoting recovery of motor function. However, the opioids consumption was not decreased by adding distal IPACK to CACB.
This study was registered at Chinese Clinical Trial Registry ( ChiCTR2200059139 ; registration date: 26/04/2022; enrollment date: 16/11/2020; http://www.chictr.org.cn ).
全膝关节置换术(TKA)的最佳镇痛需要在保留肌肉力量的同时提供良好的镇痛效果。本研究旨在验证以下假设,即连续收肌管阻滞(CACB)联合膝后皮神经与关节囊间间隔阻滞(IPACK)可有效缓解膝关节后痛,减少阿片类药物的消耗,并促进早期康复和出院。
将接受单侧初次 TKA 的患者分为 CACB+SHAM 组(接受 CACB 加 sham 阻滞)或 CACB+IPACK 组(接受 CACB 加 IPACK 阻滞)。主要结局指标为累积阿片类药物消耗量。次要结局指标包括术后膝关节后痛的发生率、视觉模拟评分(VAS)、关节活动度、步行距离和疼痛管理满意度。
在 TKA 后 4 小时(17.1%比 42.8%;p=0.019)、8 小时(11.4%比 45.7%;p=0.001)和 24 小时(11.4%比 34.3%;p=0.046),CACB+IPACK 组的中重度膝关节后痛发生率低于 CACB+SHAM 组。TKA 后 4 小时(2[2]比 3[2-4];p=0.000)、8 小时(1[1,2]比 3[2-4];p=0.001)和 24 小时(1[0-2]比 2[1-4];p=0.002),CACB+IPACK 组的膝关节后 VAS 评分低于 CACB+SHAM 组。TKA 后 4 小时(3[2,3]比 3[3,4];p=0.013)和 8 小时(2[2,3]比 3[2-4];p=0.032)时,静息状态下总体 VAS 评分低于 CACB+SHAM 组,4 小时时(3[3,4]比 4[4,5];p=0.001)、8 小时时(3[2-4]比 4[3-5];p=0.000)和 24 小时时(2[2,3]比 3[2-4];p=0.001)时主动活动时的 VAS 评分也低于 CACB+SHAM 组。术后第 1 天,CACB+IPACK 组的关节活动度(59.11±3.90 比 53.83±5.86;p=0.000)和步行距离(44.60±4.87 比 40.83±6.65;p=0.009)均优于 CACB+SHAM 组。疼痛管理满意度在 CACB+IPACK 组(9[8,9]比 8[7-9];p=0.024)中高于 CACB+SHAM 组。两组之间累积阿片类药物消耗量无差异[120(84-135)比 120(75-135);p=0.835]。
CACB 联合膝后皮神经与关节囊间间隔阻滞可降低膝关节后痛的发生率,改善 TKA 后 24 小时内的术后疼痛,并促进运动功能的恢复。然而,在 CACB 中添加膝后皮神经与关节囊间间隔阻滞并不能减少阿片类药物的消耗。
本研究在中国临床试验注册中心(ChiCTR2200059139;注册日期:2022 年 4 月 26 日;登记日期:2020 年 11 月 16 日;网址:http://www.chictr.org.cn)进行了注册。